ILCA warmly thanks all Partners and Sponsors for their unrestricted support to the 2013 Annual Conference and their commitment to help advance liver cancer science.
Bayer HealthCare and Onyx Pharmaceuticals are committed to cancer research and treatment options. We continually apply our experience, knowledge and passion to develop new cancer therapies.
About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer’s oncology franchise now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways.
Biocompatibles, with its heritage of leadership and innovation in interventional oncology, is now a BTG International group company. We are investing in product development and clinical trials to deliver on a shared vision of excellence in interventional medicine. For further information about BTG please visit our website at www.btgplc.com
Celsion is committed to the development and commercialization of innovative tumor-targeting oncology treatments that combine focused heat energy with Celsion’s proprietary heat-activated liposomal drug technology most often to treat difficult solid lesions. Research, license, and commercialization agreements include: NIH, Duke University Medical Center, University of Hong Kong, University of Pisa, UCLA Department of Medicine, Kyungpook National University Hospital, Beijing Cancer Hospital and the University of Oxford.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of people around the world in their fight against cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, psychiatric disorders and rheumatoid arthritis.
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. The Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies.
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. The company is focusing its proprietary resources and development efforts exclusively on cabozantinib.
Jennerex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. The Company’s lead product candidate, Pexa-Vec (JX-594), is currently being evaluated in an international, randomized Phase 2b study (TRAVERSE) for the treatment of HCC in patients who failed prior therapy with sorafenib
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.